Clinical trial
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of BHV-7000 Monotherapy in Major Depressive Disorder
NCT06419608 is registered in ClinicalTrials.gov with Biohaven Therapeutics Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of BHV-7000 Monotherapy in Major Depressive Disorder
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 28, 2024
- Completion date
- November 7, 2025
- Enrollment
- 336 (actual)
- Sites
- 62
Conditions
As the registry lists them; a condition with its own page is linked.